Resources
14 Results (showing 11 - 14)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 1/20/2021 (updated 9/2/2021)
People who use drugs (PWUD) in the U.S. experience disproportionate adverse health outcomes and mortality as compared with the population as a whole (Lake & Kennedy, 2016; Reisinger, Pratt, Shoenborn, & Druss, 2017). Similar health outcomes have been reported elsewhere, for example in the UK (Neale, 2004), and across 8 other European countries (Bargagli et al., 2006). In the U.S. health outcomes among PWUD are intensified by the overdose pandemic, epidemic rates of HIV, hepatitis A and C, skin and soft tissue infections (CDC Centers for Disease Control and Prevention, 2020; Hagen, Thiede, & Des Jarlais, 2005; Scholl, Seth, Kariisa, Wilson, & Baldwin, 2019), and by structural barriers thwarting health access and utilization.
Posted 12/29/2020 (updated 9/2/2021)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.
Posted 10/23/2020 (updated 9/2/2021)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 10/19/2020 (updated 9/2/2021)
JBS can facilitate additional technical assistance and support related prescribing medication for opioid use disorder (MOUD). This support is recommended for clinicians who are contemplating or have recently begun prescribing MOUD and would like additional support.